AR101669A1 - Constructos de anticuerpos para cdh19 y cd3 - Google Patents
Constructos de anticuerpos para cdh19 y cd3Info
- Publication number
- AR101669A1 AR101669A1 ARP150102450A ARP150102450A AR101669A1 AR 101669 A1 AR101669 A1 AR 101669A1 AR P150102450 A ARP150102450 A AR P150102450A AR P150102450 A ARP150102450 A AR P150102450A AR 101669 A1 AR101669 A1 AR 101669A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody construct
- provides
- human
- cdh19
- polynucleotide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
La presente proporciona un constructo de anticuerpo biespecífico que comprende un primer dominio de ligación humano que se liga al CDH19 (proteína transmembrana de caderina tipo II) humano sobre la superficie de una célula objetivo y un segundo dominio de ligación que se liga a la CD3 (antígeno CD3) humana sobre la superficie de una célula T. Por otra parte proporciona un polinucleótido que codifica el constructo de anticuerpo, un vector que comprende el polinucleótido y una célula hospedera transformada o transfectada con el polinucleótido o vector. Adicionalmente, proporciona un proceso para la producción del constructo de anticuerpo, un uso médico del constructo de anticuerpo y un kit que comprende el constructo de anticuerpo. Composición farmacéutica.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462031770P | 2014-07-31 | 2014-07-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR101669A1 true AR101669A1 (es) | 2017-01-04 |
Family
ID=53969339
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150102450A AR101669A1 (es) | 2014-07-31 | 2015-07-30 | Constructos de anticuerpos para cdh19 y cd3 |
Country Status (10)
Country | Link |
---|---|
US (2) | US9765157B2 (es) |
EP (1) | EP3186279B1 (es) |
JP (1) | JP6726168B2 (es) |
AR (1) | AR101669A1 (es) |
AU (1) | AU2015295239B2 (es) |
CA (1) | CA2953530C (es) |
MX (2) | MX2017001402A (es) |
TW (1) | TW201607959A (es) |
UY (1) | UY36245A (es) |
WO (1) | WO2016016412A1 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3375790A1 (en) * | 2008-10-01 | 2018-09-19 | Amgen Research (Munich) GmbH | Cross-species-specific single domain bispecific single chain antibody |
AU2009299791B2 (en) * | 2008-10-01 | 2016-02-25 | Amgen Research (Munich) Gmbh | Cross-species-specific PSCAxCD3, CD19xCD3, C-METxCD3, EndosialinxCD3, EpCAMxC D3, IGF-1RxCD3 or FAPalpha xCD3 bispecific single chain antibody |
ES2728936T3 (es) | 2013-01-25 | 2019-10-29 | Amgen Inc | Anticuerpos dirigidos contra CDH19 para melanoma |
ES2889906T3 (es) | 2015-05-21 | 2022-01-14 | Harpoon Therapeutics Inc | Proteínas de unión triespecíficas y usos médicos |
JP2018518491A (ja) * | 2015-06-12 | 2018-07-12 | アレクトル エルエルシー | 抗cd33抗体及びその使用方法 |
TWI796283B (zh) * | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Msln及cd3抗體構築體 |
TW202346349A (zh) | 2015-07-31 | 2023-12-01 | 德商安美基研究(慕尼黑)公司 | Dll3及cd3抗體構築體 |
EA201892693A1 (ru) * | 2016-05-20 | 2019-04-30 | Харпун Терапьютикс, Инк. | Белки, содержащие одноцепочечный вариабельный фрагмент, связывающийся с cd3 |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
EA201892691A1 (ru) | 2016-05-20 | 2019-04-30 | Харпун Терапьютикс, Инк. | Однодоменный белок, связывающий сывороточный альбумин |
MX2019006045A (es) | 2016-11-23 | 2019-11-11 | Harpoon Therapeutics Inc | Proteinas triespecificas dirigidas a psma y metodos de uso. |
MX2019006043A (es) | 2016-11-23 | 2019-09-26 | Harpoon Therapeutics Inc | Proteína de unión de antígeno prostático específico de membrana. |
US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
CN110891974B (zh) | 2017-05-12 | 2021-08-06 | 哈普恩治疗公司 | 间皮素结合蛋白质 |
WO2018209304A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Msln targeting trispecific proteins and methods of use |
EP3589658A1 (en) | 2017-08-03 | 2020-01-08 | Alector LLC | Anti-cd33 antibodies and methods of use thereof |
CN111630070A (zh) | 2017-10-13 | 2020-09-04 | 哈普恩治疗公司 | 三特异性蛋白质及使用方法 |
JP7066837B2 (ja) | 2017-10-13 | 2022-05-13 | ハープーン セラピューティクス,インク. | B細胞成熟抗原結合タンパク質 |
AU2019346466A1 (en) | 2018-09-25 | 2021-05-20 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
IL295448A (en) | 2020-02-21 | 2022-10-01 | Harpoon Therapeutics Inc | flt3 binding proteins and methods of use |
RS64645B1 (sr) | 2020-02-26 | 2023-10-31 | Vir Biotechnology Inc | Antitela protiv sars-cov-2 |
CN113461821B (zh) * | 2021-09-03 | 2021-12-28 | 苏州近岸蛋白质科技股份有限公司 | 抗cd3人源化抗体 |
WO2023147470A2 (en) * | 2022-01-28 | 2023-08-03 | Georgiamune Inc. | Antibodies to programmed cell death protein 1 that are pd-1 agonists |
Family Cites Families (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
ATE120761T1 (de) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
US5683888A (en) | 1989-07-22 | 1997-11-04 | University Of Wales College Of Medicine | Modified bioluminescent proteins and their use |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5292658A (en) | 1989-12-29 | 1994-03-08 | University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center | Cloning and expressions of Renilla luciferase |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5612205A (en) | 1990-08-29 | 1997-03-18 | Genpharm International, Incorporated | Homologous recombination in mammalian cells |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0546073B1 (en) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production and use of transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0575319B1 (en) | 1991-03-11 | 1999-11-10 | The University Of Georgia Research Foundation, Inc. | Cloning and expression of renilla luciferase |
WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1993015722A1 (en) | 1992-02-07 | 1993-08-19 | Syntex (Usa) Inc. | Controlled delivery of pharmaceuticals from preformed porous microparticles |
JPH07508410A (ja) | 1992-06-18 | 1995-09-21 | ジェンファーム インターナショナル インコーポレイテッド | 酵母人工染色体を有するトランスジェニック非ヒト動物の製造方法 |
EP0652950B1 (en) | 1992-07-24 | 2007-12-19 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
NZ257942A (en) | 1992-10-23 | 1996-04-26 | Immunex Corp | Preparing a mammalian protein by expression of a fusion protein containing a leucine zipper domain |
US5981175A (en) | 1993-01-07 | 1999-11-09 | Genpharm Internation, Inc. | Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome |
WO1995007463A1 (en) | 1993-09-10 | 1995-03-16 | The Trustees Of Columbia University In The City Of New York | Uses of green fluorescent protein |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
WO1995021191A1 (en) | 1994-02-04 | 1995-08-10 | William Ward | Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein |
US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US5777079A (en) | 1994-11-10 | 1998-07-07 | The Regents Of The University Of California | Modified green fluorescent proteins |
JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク. | 免疫したゼノマウス(XenoMouse)に由来するヒト抗体 |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
DK0843961T3 (da) | 1995-08-29 | 2007-05-21 | Kirin Brewery | Kimærisk mus og fremgangsmåde til at producere samme |
US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
US5804387A (en) | 1996-02-01 | 1998-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | FACS-optimized mutants of the green fluorescent protein (GFP) |
US5876995A (en) | 1996-02-06 | 1999-03-02 | Bryan; Bruce | Bioluminescent novelty items |
US5925558A (en) | 1996-07-16 | 1999-07-20 | The Regents Of The University Of California | Assays for protein kinases using fluorescent protein substrates |
US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
KR100643058B1 (ko) | 1996-12-03 | 2006-11-13 | 아브게닉스, 인크. | 복수의 Vн 및 Vк 영역을 함유하는 인간 면역글로불린 유전자좌를 갖는 트랜스제닉 포유동물 및 이로부터 생성된 항체 |
ATE290205T1 (de) | 1996-12-12 | 2005-03-15 | Prolume Ltd | Vorrichtung und verfahren zum nachweis und identifizieren von infektiösen wirkstoffen |
CA2290485C (en) | 1997-05-21 | 2008-08-05 | Biovation Limited | Method for the production of non-immunogenic proteins |
AU765703B2 (en) | 1998-03-27 | 2003-09-25 | Bruce J. Bryan | Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items |
ID27512A (id) | 1998-04-21 | 2001-04-12 | Microment Ges Fur Biomedizinis | Polipeptid tetapan cd19xcd3 dan kegunaan-kegunaannya |
CN1202128C (zh) | 1998-12-08 | 2005-05-18 | 拜奥威神有限公司 | 修饰蛋白的免疫原性 |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
WO2004003019A2 (en) * | 2002-06-28 | 2004-01-08 | Domantis Limited | Immunoglobin single variant antigen-binding domains and dual-specific constructs |
DK1461442T3 (en) | 2001-11-30 | 2017-12-04 | Amgen Fremont Inc | Transgenic animals with human Ig lambda light chain genes |
WO2005067391A2 (en) | 2004-01-19 | 2005-07-28 | Technion Research & Development Foundation Ltd. | Diagnostic test for parkinson's disease |
AU2005322410B2 (en) * | 2004-11-30 | 2011-11-10 | Amgen Fremont Inc. | Antibodies directed to GPNMB and uses thereof |
WO2006138181A2 (en) | 2005-06-14 | 2006-12-28 | Amgen Inc. | Self-buffering protein formulations |
EP1940881B1 (en) | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
CN101687915B8 (zh) * | 2007-04-03 | 2018-08-03 | 安进研发(慕尼黑)股份有限公司 | 跨物种特异性CD3-ε结合结构域 |
CA2740310A1 (en) | 2007-11-01 | 2009-05-07 | The Royal Institution For The Advancement Of Learning/Mcgill University | Altered cadherin processing in tumor cells |
KR20150082422A (ko) | 2012-11-08 | 2015-07-15 | 노보자임스 바이오파마 디케이 에이/에스 | 알부민 변이체 |
JO3519B1 (ar) * | 2013-01-25 | 2020-07-05 | Amgen Inc | تركيبات أجسام مضادة لأجل cdh19 و cd3 |
ES2728936T3 (es) * | 2013-01-25 | 2019-10-29 | Amgen Inc | Anticuerpos dirigidos contra CDH19 para melanoma |
JP6071725B2 (ja) | 2013-04-23 | 2017-02-01 | カルソニックカンセイ株式会社 | 電気自動車の駆動力制御装置 |
US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
-
2015
- 2015-07-30 UY UY0001036245A patent/UY36245A/es not_active Application Discontinuation
- 2015-07-30 AR ARP150102450A patent/AR101669A1/es unknown
- 2015-07-31 US US14/815,861 patent/US9765157B2/en active Active
- 2015-07-31 EP EP15753906.5A patent/EP3186279B1/en active Active
- 2015-07-31 WO PCT/EP2015/067610 patent/WO2016016412A1/en active Application Filing
- 2015-07-31 TW TW104124830A patent/TW201607959A/zh unknown
- 2015-07-31 AU AU2015295239A patent/AU2015295239B2/en active Active
- 2015-07-31 MX MX2017001402A patent/MX2017001402A/es unknown
- 2015-07-31 JP JP2017505097A patent/JP6726168B2/ja active Active
- 2015-07-31 CA CA2953530A patent/CA2953530C/en active Active
-
2017
- 2017-01-30 MX MX2021008367A patent/MX2021008367A/es unknown
- 2017-08-10 US US15/673,539 patent/US20180002450A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20160032019A1 (en) | 2016-02-04 |
US20180002450A1 (en) | 2018-01-04 |
EP3186279B1 (en) | 2024-01-10 |
UY36245A (es) | 2016-01-29 |
TW201607959A (zh) | 2016-03-01 |
JP6726168B2 (ja) | 2020-07-22 |
WO2016016412A1 (en) | 2016-02-04 |
JP2017522892A (ja) | 2017-08-17 |
MX2021008367A (es) | 2021-08-11 |
CA2953530C (en) | 2023-01-03 |
CA2953530A1 (en) | 2016-02-04 |
EP3186279A1 (en) | 2017-07-05 |
US9765157B2 (en) | 2017-09-19 |
AU2015295239B2 (en) | 2021-05-20 |
EP3186279C0 (en) | 2024-01-10 |
MX2017001402A (es) | 2017-08-28 |
AU2015295239A1 (en) | 2017-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR101669A1 (es) | Constructos de anticuerpos para cdh19 y cd3 | |
CL2021000716A1 (es) | Constructos de anticuerpo para flt3 y cd3. (divisional sol. 201800269) | |
CO2018000976A2 (es) | Constructos de anticuerpo para cd70 y cd3 | |
CO2018000887A2 (es) | Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3 | |
AR101400A1 (es) | Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido | |
CL2020003416A1 (es) | Constructos de anticuerpo biespecificos que se unen a mesotelina y cd3 (divisional sol. 201800268) | |
CO2018000877A2 (es) | Constructos de anticuerpo biespecificos que se unen a dll3 y cd3 | |
BR112018015670A2 (pt) | construtos de anticorpo biespecíficos envolvendo células t | |
CR20150437A (es) | Construcciones de anticuerpos para cdh19 y cd3 | |
MX2020004027A (es) | Anticuerpos especificos cd47/pd-l1. | |
DOP2019000165A (es) | Anticuerpos anti-ox40 y sus usos | |
CL2017002641A1 (es) | Construcciones de anticuerpos biespecíficos contra cdh3 y cd3 | |
BR112018003186A2 (pt) | anticorpos anti-pd-1 e seus métodos de uso | |
BR112018074463A2 (pt) | anticorpos anti-tim-3 e métodos de uso dos mesmos. | |
BR112017025564A2 (pt) | anticorpos anti-ctla-4 e métodos de uso dos mesmos | |
UY35964A (es) | Anticuerpos humanos para pd?1 | |
CO2018011195A2 (es) | Composiciones que comprenden una coformulación de anticuerpos anti-pd-l1 y anti-ctla-4 | |
UY35456A (es) | Moléculas de unión para bcma y cd3 | |
AR090668A1 (es) | Anticuerpo anti-adamts-5, derivados y usos del mismo | |
MX2020004512A (es) | Anticuerpos anti apolipoproteina c-iii (anti-apoc3) y metodos de uso de los mismos. | |
AR105559A1 (es) | Constructos de anticuerpo para cd70 y cd3 | |
AR105561A1 (es) | Constructos de anticuerpo para el receptor de la tirosina quinasa (flt3) y el antígeno cd3 | |
AR105558A1 (es) | Constructos de anticuerpo para dll3 y cd3 | |
AR105562A1 (es) | Constructos de anticuerpo para receptor del factor de crecimiento epidérmico variante viii (egfrviii) y el antígeno cd3 | |
AR105560A1 (es) | Constructos de anticuerpo para msln y cd3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |